Comparative Pharmacology
Head-to-head clinical analysis: BROMPHENIRAMINE MALEATE versus VISTARIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BROMPHENIRAMINE MALEATE versus VISTARIL.
BROMPHENIRAMINE MALEATE vs VISTARIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive antagonist of histamine at H1 receptor sites, suppressing histamine-induced vasodilation, increased capillary permeability, and bronchoconstriction.
Hydroxyzine is a piperazine derivative antihistamine that acts as a competitive antagonist of histamine H1 receptors, thereby suppressing histamine activity in the subcortical area of the central nervous system. It also has anxiolytic, sedative, antiemetic, and antispasmodic effects.
4 mg orally every 4-6 hours, not to exceed 24 mg/day. Alternatively, extended-release: 12 mg every 12 hours.
Oral: 50-100 mg 4 times daily; IM: 25-100 mg every 4-6 hours as needed.
None Documented
None Documented
Terminal half-life 22-25 hours; prolonged in hepatic impairment or elderly (up to 40 hours).
Terminal elimination half-life: 20-25 hours in adults; prolonged in hepatic impairment or elderly; steady-state achieved in ~4-5 days.
Renal (85-90% as metabolites, 5-10% unchanged); biliary/fecal <5%.
Primarily hepatic metabolism; <1% excreted unchanged in urine; biliary/fecal elimination of metabolites accounts for approximately 50-60% of total clearance.
Category C
Category C
Antihistamine
Antihistamine